KCa3.1 channel in brain immune cells and Parkinson's disease
The Role of KCa3.1 in Microglial function and in Parkinsons disease pathogenesis
This work looks at whether blocking a protein called KCa3.1 can lower harmful brain inflammation linked to Parkinson's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11328777 on NIH RePORTER |
What this research studies
Researchers focus on microglia, the brain's immune cells, and a potassium channel called KCa3.1 that is increased in Parkinson's disease brains. They use human brain tissue observations, cell experiments, and mouse models that mimic Parkinsonian pathology to study how KCa3.1 changes microglial responses to misfolded alpha‑synuclein. The team tests a drug called Senicapoc, which selectively blocks KCa3.1, to see if it reduces inflammation and protects dopamine-producing neurons in preclinical models. They also explore signaling pathways (including FYN and STAT1) that control how microglia become reactive in Parkinsonian conditions.
Who could benefit from this research
Good fit: People diagnosed with Parkinson's disease, especially those earlier in their disease course, would be the most relevant candidates for future therapies emerging from this work.
Not a fit: People without Parkinson's disease or those with very advanced disease where most neurons are already lost may not benefit from KCa3.1-targeting approaches.
Why it matters
Potential benefit: If successful, this work could point to new anti-inflammatory treatments that slow neurodegeneration and preserve function in people with Parkinson's disease.
How similar studies have performed: Preclinical mouse studies reported that the KCa3.1 blocker Senicapoc reduced neuroinflammation and protected dopamine neurons, but human trials in Parkinson's have not yet been established.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Kanthasamy, Arthi — University of Georgia
- Study coordinator: Kanthasamy, Arthi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.